Life sciences

Freedom of information request shows Biomedical Catalyst is backing only 4% of applications assessed as worthy of funding

The life science industry is all hands on deck in the race to develop vaccines, therapies and diagnostics in the fight against coronavirus. But while some prosper, many in the sector are forced to halt clinical trials and mothball labs

Low profitability of antibiotics means fight against drug resistance relies on a handful of companies

Investment in later stage clinical development is needed to back up recent improvements in the discovery of new antibiotics, and to ensure the use of novel products is managed to maintain their effectiveness